Freud, whose dream studies focused on interpreting dreams, not explaining how or why humans dream, disputed Roberts hypothesis and proposed that dreams preserve sleep by representing as fulfilled those wishes that otherwise would awaken the dreamer. Freud wrote that dreams "serve the purpose of prolonging sleep instead of waking up. Dreams are the GUARDIANS of sleep and not its disturbers." A turning point in theorizing about dream function came in 1953, when Science published the Aserinsky and Kleitman paper establishing REM sleep as a distinct phase of sleep and linking dreams to REM sleep. Until and even after publication of the Solms 2000 paper that certified the separability of REM sleep and dream phenomena, many studies purporting to uncover the function of dreams have in fact been studying not dreams but measurable REM sleep.
For patients, this has the major benefit that they can take less saquinavir, while maintaining sufficient saquinavir blood plasma levels to efficiently suppress the replication of HIV.The mechanism behind this welcome observation was not directly known, but later it was determined that ritonavir inhibits the cytochrome P450 3A4 isozyme. Normally, this enzyme metabolizes saquinavir to an inactive form, but with the ritonavir inhibiting this enzyme, the saquinavir blood plasma levels increased considerably. Additionally, ritonavir also inhibits multidrug transporters, although to a much lower extent.Unlike other protease inhibitors, the absorption of saquinavir seems to be improved by omeprazole. Mechanism of action
Saquinavir is a protease inhibitor. Proteases are enzymes that cleave protein molecules into smaller fragments. HIV protease is vital for both viral replication within the cell and release of mature viral particles from an infected cell. Saquinavir binds to the active site of the viral protease and prevents cleavage of viral polyproteins, preventing maturation of the virus. Saquinavir inhibits both HIV-1 and HIV-2 proteases. History
Saquinavir was developed by the pharmaceutical company Roche. Saquinavir was the sixth antiretroviral and the first protease inhibitor approved by the US Food and Drug Administration (FDA), leading ritonavir and indinavir by a few months.